Eversept Partners LP cut its stake in Sanofi SA (NYSE:SNY) by 20.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 266,062 shares of the company’s stock after selling 66,340 shares during the period. Sanofi comprises about 3.3% of Eversept Partners LP’s investment portfolio, making the stock its 10th largest position. Eversept Partners LP’s holdings in Sanofi were worth $11,513,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Lazard Asset Management LLC grew its holdings in Sanofi by 47,594.3% during the 1st quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock worth $105,595,000 after acquiring an additional 2,379,716 shares in the last quarter. Schafer Cullen Capital Management Inc grew its holdings in Sanofi by 106.8% during the 2nd quarter. Schafer Cullen Capital Management Inc now owns 728,871 shares of the company’s stock worth $30,088,000 after acquiring an additional 376,410 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Sanofi by 2.2% during the 2nd quarter. Fisher Asset Management LLC now owns 16,868,423 shares of the company’s stock worth $729,897,000 after acquiring an additional 367,961 shares in the last quarter. Richard C. Young & CO. LTD. bought a new position in Sanofi during the 1st quarter worth about $8,583,000. Finally, FMR LLC grew its holdings in Sanofi by 1.9% during the 1st quarter. FMR LLC now owns 9,233,558 shares of the company’s stock worth $408,862,000 after acquiring an additional 175,580 shares in the last quarter. Hedge funds and other institutional investors own 7.04% of the company’s stock.
Several brokerages have issued reports on SNY. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Friday, June 21st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Tuesday, August 6th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Thursday, August 29th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Thursday, August 29th. Finally, Sanford C. Bernstein assumed coverage on shares of Sanofi in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $52.00 price target for the company. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Sanofi has an average rating of “Buy” and an average target price of $49.67.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Monday, July 29th. The company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.07. The business had revenue of $8.63 billion during the quarter, compared to analyst estimates of $8.42 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.25 earnings per share. As a group, equities analysts forecast that Sanofi SA will post 3.1 EPS for the current fiscal year.
In related news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.00% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: What is Net Asset Value (NAV)?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.